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Alzheimer’s disease (AD) is characterized by the presence
of amyloid plaques and tau fibrils, which are associated with
synaptic loss and neurodegeneration, leading to cognitive im-
pairments and dementia. After age, family history, and apoli-
poprotein E (APOE) ε4 risk allele [1], traumatic brain injury
(TBI) has been reported as a risk factor in many [2–33] but
not all [13] epidemiological studies (reviewed in [34–36]).
Some studies have suggested that a history of TBI is
associated with earlier onset of AD [3,6,13,18,20,34,35,37].
Others, but not all, have shown an interaction of TBI with
the APOE ε4 allele [5,6,15,17,38–46]. After TBI, young
subjects appear to have had Ab pathology in postmortem
brain tissue [47,48]. A comprehensive consensus analysis of
the literature concluded that there was some evidence for a
relationship between TBI in males and future development
of AD (odds ratio 2.29 [1.47–3.58]) [20]. One study [33],
which showed a significantly increased risk of developing
AD after TBI, used information provided by the US Depart-
ment of Defense to identify and prospectively enroll subjects
with nonpenetrating head injury suffered during WWII and
the Korean War, and non–head-injured controls. Recently,
one study from the Mayo Clinic Study of Aging [49] sug-
gested that MCI, but not cognitively normal subjects, who
reported a history of concussion had higher brain Ab levels,
measured with Ab positron emission tomography (PET)
scans, than noninjured MCI participants. With the exception
of one publication [50], studies of the effects of TBI on AD
have used “self-report” information to determine a history of
concussion; few studies have used imaging and cerebrospinal
fluid biomarkers to investigate the relationship of TBI to AD.
Posttraumatic stress disorder (PTSD) is an anxiety disorder
following exposure to traumatic stress [51]. The prevalence of
combat-related PTSD in US military Veterans since the Viet-
nam War ranges from 10% to 15% [52,53]. PTSD is
associated with worse cognitive functioning [50,54–62].
Furthermore, PTSD is associated with alterations in the
hippocampus [63–67], anterior cingulate [65], and prefrontal
structures [63–69], whereas improvement of symptoms is
associated with less-progressive atrophy [67]. The relationship
of PTSD to impaired cognitive function and hippocampal ab-
normalities suggests that PTSD could be a risk factor for the
development of AD. A study of the national Veterans Admin-
istration (VA) clinical database showed that Veterans with
PTSD are twice as likely to develop a dementia diagnosis
compared to Veterans without PTSD, even when controlling
for known risk factors for dementia [70]. Aside from magnetic
resonance imaging (MRI) studies, to our knowledge, there are
no reports of the use of Ab PET scans or other biomarkers to
examine whether the mechanism accounting for the higher
risk for dementia in PTSD is related to AD pathology.
The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
is a large, multisite study, aimed at validating biomarkers for
AD clinical trials. ADNI has enrolled over 1500 subjects at 57
sites in the United States and Canada and followed themlongitudinally with clinical/cognitive testing, genetic anal-
ysis, MRI, lumbar puncture for cerebrospinal fluid (CSF)
analysis, 18F-fluorodeoxyglucose PET, Ab PET, and most
recently tau-PET (reviewed in [71]). To investigate the rela-
tionship of a past history of TBI and PTSD on the develop-
ment of AD, the Department of Defense funded three
proposals: (1) Effects of Traumatic Brain Injury (TBI) and
Posttraumatic Stress Disorder on Alzheimer’s Disease in Vet-
erans Using Imaging and Biomarkers in the AD Neuroimag-
ing Initiative; (2) Effects of Traumatic Brain Injury and
Posttraumatic Stress Disorder on Alzheimer’s Disease in Vet-
erans withMild Cognitive Impairment Using the Alzheimer’s
Disease Neuroimaging Initiative; and (3) Effects of Traumatic
Brain Injury and Posttraumatic Stress Disorder and
Alzheimer’s Disease on Brain Tau in VietnamVeterans Using
ADNI. These studies are collectively termed “DOD ADNI,”
and aim to enroll approximately 400 elderly Veterans who
served in Vietnam.
The initial DOD ADNI grant enrolled Vietnam Veterans
with PTSD and/or TBI, as well as controls with service-
connected disorders not related to PTSD or TBI who met
criteria for normal cognition. The second grant expanded
the original study to include subjects who also met criteria
for MCI. The study now includes cohorts of Vietnam Veter-
ans, both with and without MCI, who have histories of TBI,
PTSD, and both TBI and PTSD, as well as controls without
PTSD/TBI. Potential subjects are initially contacted bymail,
prescreened for eligibility by telephone and those meeting
criteria for one of the cohorts are referred for clinical
examination, cognitive tests, Ab PET using 18F-labeled flor-
betapir, MRI (structural, diffusion tensor, and resting state
functional), lumbar puncture for CSF markers of tau, phos-
phorylated tau (p-tau181), b-amyloid (Ab42), and blood
collection for genetic analysis. The clinical/cognitive battery
and MRI is repeated after 1 year, and tau-PET scans are
obtained at baseline and after 1 year. Results from the CSF
assays and tau-PET imaging are pending and will not be
reported in this article.
This interim report uses baseline data to determine the
extent to which a prior history of TBI and/or documented
past history and present diagnosis of PTSD increase the risk
ofdevelopingAD.Our primary a priori hypothesis is thatViet-
nam Veterans with a history of TBI or presence of ongoing
PTSD will have lower cognitive functioning and increased
prevalence of brain AD pathology (measured by Ab florbeta-
pir PET and medial temporal lobe atrophy) after accounting
for effects of age and presence of the APOE ε4 allele.2. Methods
2.1. Identification of potential study subjects
For this study, we used an operational definition of TBI as
head injurywith loss of consciousness formore than 5minutes,
and/or having amnesia, and/or being dazed and confused for
more than 24 hours. Using military and VA Compensation
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response to advertisements, Vietnam Veterans with a service
connection related to a possible traumatic head injury and/or
a history of at least one moderate/severe TBI and/or evidence
of ongoing PTSD, and demographically comparable Veteran
controls without PTSD/TBI were identified. Because TBI
was not a common diagnostic code during the Vietnam War,
the study requested a sample of subjects from the Veteran Ben-
efits Administration who were service-connected for several
diagnostic codes that might be related to a traumatic brain
injury (traumatic brain disease, posttrauma headache, acute
posttrauma headache, chronic posttrauma headache, post-
concussion syndrome, brain hemorrhage, limited motion of
the jaw, and other head-related injuries). We also obtained
separate samples of subjects who are service-connected for
PTSD as well as a sample of controls who were service-
connected for something other than PTSD or TBI. Study invi-
tation letters, brochures, and response postcards weremailed to
Veterans who met these initial broad criteria and who lived
within 150 miles of the closest ADNI clinic.2.2. Initial telephone prescreening recruitment calls
To include all subjects whomay have a history of a TBI and
to confirm whether or not the TBI-related diagnostic codes
were related to a head injury, all subjects were contacted by
telephone, and verbal consent was obtained for the administra-
tion of screening questions which determined eligibility
criteria for current PTSD symptoms and history of a TBI.
The Ohio State University TBI Identification Method–Inter-
view Form [72] was used to ask about head injuries at three
separate times in a subject’s life: before, during, and after Viet-
nam. This ensured we included TBIs that may have occurred
before or after a subject’s military service. In addition, a safety
assessment ruled out subjects whowere not safe to participate
in the study procedures. The purpose of the initial telephone
prescreening recruitment call was both to (1) rule out exclu-
sions such as dementia, historyofpsychosis orbipolar affective
disorder, history of schizophrenia (Diagnostic and Statistical
Manual of Mental Disorders, 4th edition criteria), history of
alcohol or substance abuse/dependencewithin the past 5 years,
MRI-related exclusions (metal in the body, pacemakers), con-
traindications for lumbar puncture, PET scan, or other proced-
ures in this study and (2) assess placement in study cohorts.
During this initial screen, MCI was assessed using an adapted
version of the AD8 (70, 71) and the Telephone Interview for
Cognitive Status, as the latter contains a 10-word list recall
which combined with the AD8 can help to identify cognitive
impairment [73,74]. Subjects meeting inclusion criteria were
then mailed a written consent form for the telephone
psychiatric assessment (clinical interview) portion of the
study and audio recording, with a stamped addressed return
envelope and the following self-report questionnaires: (1)
MRI safety, (2) Medical history, (3) Current medications, (4)
SymptomCheckList 90 (revised) for general psychopathology
[75], (5) Pittsburgh SleepQuality [76], (6) Smoking/Life TimeSmoking, (6) SF-12Health Survey [77], and (7)Combat Expo-
sure Scale [78].
After documented consent was received, all self-report
questionnaires described previously were reviewed as well
as the subjects’ VA medical records to ensure that there
were no medical problems or exclusionary medications
that the subject failed to report and to ensure that proper
cohort assignment had been determined. VAmedical records
were reviewed for any documentary evidence of a TBI at
anytime in a subject’s life regardless of whether or not a sub-
ject reported a TBI during the administration of the Ohio
State University TBI Identification Method–Interview
Form. If the medical records specifically mentioned a TBI
incident or a service connection related to a TBI (as indi-
cated by the diagnostic codes discussed previously), or if a
subject self-reported a TBI (that met the operational criteria
of TBI discussed previously) during anytime in the subject’s
life, this subject was not placed in the control group.
2.3. SCID CAPS evaluation by telephone
All eligible subjects were next referred to the telephone
clinical evaluation which used the Structured Clinical Inter-
view 1 of the Diagnostic and Statistical Manual of Mental
Disorders, Version IV, (Axis 1)–Text Revision (SCID) and
the Clinician Administered PTSD Scale for DSM-IV
(CAPS) [79] to assess current and lifetime PTSD and to
rule out psychosis and/or drug and alcohol issues. SCID
CAPS, as well as the Life Stressor Checklist [80] and the
Addiction Severity Index Lite [81], was conducted by
telephone by the PTSD Core at the San Francisco Veterans
Administration Medical Center.
2.4. Assignment of subjects to cohorts
After completing the SCID CAPS, eligible subjects were
placed into one of eight cohorts, four with no MCI and four
whomet initial criteria forMCI, as described in the following:
 TBI only: Subjects with no service connection for
PTSD, no history of lifetime, and/or current PTSD
on SCID CAPS (scores of,30 for each) but with a ser-
vice connection for a TBI-related diagnostic code,
medical documentation of a TBI-related incident,
and/or a self-report of a TBI which met the operational
definition of TBI described previously.
 PTSD only: Subjects who were service-connected for
PTSD and who scored 40 for both lifetime and
current PTSD, with no self-report history of TBI, no
diagnostic service connection related to TBI, and no
medical documentation of TBI.
 Both TBI1 PTSD: Subjects who scored30 for either
lifetime and/or current PTSD and had a service
connection related to TBI, medical documented evi-
dence of a TBI-related incident, and/or a self-report
history of TBI meeting the operational criteria of
TBI described previously.
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PTSD, no history of lifetime, and/or current PTSD
on SCID CAPS (scores of ,30 for each), and no
service connection for TBI-related diagnostic codes,
no medical documentation of a TBI-related incident,
and no self-report of a TBI that met the operational
definition of TBI.
Eligible subjects were next referred to one of the 19
ADNI Clinic sites to sign a clinic consent and complete
study procedures.2.5. Clinical evaluation, neuropsychological testing, MRI,
and Ab florbetapir PET scans
After the clinical telephone interview, subjects were
referred to the closest ADNI site for in-person studies using
the identical methods used by ADNI. These include clinical
evaluation, neuropsychological testing, lumbar puncture (re-
sults not available at this time), genetic sampling for the
APOE ε4 allele, structural MRI at 3T, and Ab florbetapir
PET scans. These methods have been widely reported
[82–86]. Longitudinal data and tau-PET scan results will
be reported at a later time.2.6. Power analysis
Our original study was designed to have 80% power to
detect a minimum difference in means of 0.55 standard
deviations, assuming 65 participants in each group, an alpha
of 0.025, and a two-sided test. In this interim report, we have
not yet achieved our desired sample size in each group,
particularly in the TBI and TBI 1 PTSD groups. For com-
parison of the TBI group (n 5 22) with the no TBI/PTSD
group (n 5 63), we have 80% power to detect a difference
as small as 0.78 standard deviations (0.68 standard devia-
tions for the TBI 1 PTSD vs. no TBI/PTSD group).
Minimum detectable differences are larger for the imaging
outcomes, where sample sizes are even smaller.2.7. Statistical analysis
Means and standard deviations were computed for all
continuous variables of interest (age, education, neuropsycho-
logical testing,MRI volumetrics, and florbetapir standardized
uptake value ratio [SUVR]), whereas percentages were
calculated for categorical variables (gender, race/ethnicity,
diagnosis, APOE ε4 status). Analysis of variance or Fisher’s
exact test was used to compare groups (PTSD, TBI, both,
neither) on demographic and clinical characteristics. Linear
regressionwas used to compare groups onmost neuropsycho-
logical testing scores andMRI volumetrics. Volume of white-
matter hyperintensities was transformed with natural log to
meet the assumptions of the models. Poisson regression [87]
was used to compare groups on the clinical dementia rating
(CDR) Sum of Boxes because this outcome did not meet
the assumptions of linear regression. Mini–Mental StateExamination (MMSE) was rescaled as the number of errors
(30MMSE) and analyzedwith a negative binomial regression
due to overdispersion. Finally, logistic regression was used to
compare amyloid positivity based on Ab florbetapir cortical
SUVR across the groups. All models were adjusted for age,
education, and APOE ε4 status by including these variables
in themodels. Primary comparisons of interest for all analyses
were between the patient groups (PTSD, TBI, both) and the
control group (noPTSDorTBI). All analyseswere conducted
using SAS software version 9.4 [88] with a P-value ,.05
considered statistically significant.3. Results
3.1. Description of the recruitment assessment process
The number of subjects contacted by mailing brochures,
the initial telephone screening effort, including number of
subjects called and screened, the numbers of consents
mailed and SCID evaluations by telephone, and finally the
number of completed baseline clinic visits and 12-month
follow-up visits are outlined in Fig. 1.
3.1.1. Demographic and clinical characteristics
The demographic and clinical characteristics of the
cohort are given in Tables 1 and 2. The groups differed in
age, with the control group without PTSD/TBI
significantly older than the PTSD (P , .001), TBI
(P 5 .005), and TBI 1 PTSD (P , .001) groups.
Education also differed between the groups, with the
PTSD group significantly less educated than the control
group (P 5 .004). There were no differences in gender,
race/ethnicity, or APOE ε4 allele status. The percentage of
subjects with an MCI diagnosis was significantly different
across the groups (P 5 .03), with a significantly higher
percentage in the group with both TBI and PTSD and the
group with PTSD than in the controls.
In models adjusted for age, education, and APOE ε4 allele
status, there was no significant difference in verbal memory
(RAVLT, Delayed Recall), but there was a trend for a differ-
ence in global cognition (MMSE,ADAS-Cog) with the PTSD
group having worse global cognition than the controls. There
was a significant difference in CDR Sum of Boxes, with the
PTSD group (P 5 .009) and the TBI 1 PTSD group
(P 5 .007) having higher CDR Sum of Boxes scores (indi-
cating worse cognitive functioning) than the controls. This
finding and the trend for worse global cognitive function
remained even after further accounting for amyloid burden
in the brain as measured by Ab florbetapir PET (MMSE:
PTSD vs. control: P 5 .052; CDR Sum of Boxes: PTSD vs.
control: P 5 .03, TBI 1 PTSD vs. control: P 5 .008).
3.2. Brain structure measured by MRI
Table 3 describes the brain regional volumes and volume
of white-matter hyperintensities across the groups. There
were no significant differences between the groups in models
Flow of DOD ADNI Recruitment & Enrollment
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Fig. 1. Overall summary of study recruitment and enrollment. Abbreviations: ADNI, Alzheimer’s Disease Neuroimaging Initiative; PTSD, posttraumatic stress
disorder; TBI, traumatic brain injury.
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in the superior parietal region (P5 .046), which had a slightly
lower volume in the TBI 1 PTSD group than in the control
group (P5 .04). A further analysis that considered a measure
of PTSD (CAPS) rather than the specific exposure groups
found no association between level of PTSD and hippocam-
pal volume (P . .7) or superior parietal volume (P . .3)
for either the current CAPS or lifetime CAPS, in a model
that included age, education, and APOE ε4 allele status.3.3. b amyloid florbetapir positron emission tomography
Table 4 and Fig. 2 illustrate the distribution of Ab florbe-
tapir cortical SUVR across the groups. When categorized
according to amyloid positivity using a previously validated
cutoff of 1.11 [89], therewas a significant difference by group
(P5 .04) in a model adjusted for age, education, and APOEε4 allele status, with the PTSD group having significantly
lower odds of being amyloid positive (odds ratio: 0.21;
95% CI: 0.05–0.93; P 5 .04) than the controls. The propor-
tion of controls in this study classified as amyloid positive
was comparable to previous ADNI studies (data not shown).4. Discussion
The major findings of this project are as follows: (1)
worse cognitive functioning as measured by the CDR Sum
of Boxes in the PTSD and both TBI1 PTSD groups relative
to the controls; (2) a trend for worse global cognitive
functioning (ADAS-Cog, MMSE) in the PTSD group rela-
tive to the controls; (3) slightly lower superior parietal vol-
ume in the group with both TBI 1 PTSD relative to
controls; (4) lower odds of amyloid positivity based on
cortical amyloid SUVR in the PTSD group relative to the
Table 1
Participant characteristics
No TBI/PTSD (n 5 63) PTSD (n 5 63) TBI (n 5 22) TBI 1 PTSD (n 5 32) P value*
Age 71.1 (5.9) 67.8 (3.6) 67.9 (4.5) 68.7 (3.1) ,.001
Education 16.0 (2.2) 14.7 (2.5) 15.8 (2.2) 15.2 (2.4) .01
Male (%) 100 100 100 96.9 .30
Ethnicity (%) .81
African American 6.3 4.8 9.1 12.5
Asian 4.8 0 0 0
Caucasian 80.9 82.5 81.8 78.1
Hispanic 6.3 11.1 9.1 9.4
Other 1.6 1.6 0 0
E41 (%)y 25.9 30.4 36.8 29.6 .81
MCI (%)z 3.3 15.5 10.0 20.7 .03
Abbreviations: TBI, traumatic brain injury; PTSD, posttraumatic stress disorder; E41, carriers of the ε4 allele of apolipoprotein E; MCI, mild cognitive
impairment.
NOTE. Means and standard deviations are presented unless otherwise stated.
*P value presented is for the overall group difference.
yE4 data available for all but 5 No TBI/PTSD (controls), 7 PTSD, 3 TBI, and 5 TBI 1 PTSD.
zDiagnosis available for 61 No TBI/PTSD, 58 PTSD, 20 TBI, and 29 TBI 1 PTSD.
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associated with TBI and no evidence for medial temporal
lobe atrophy in those with PTSD and/or TBI relative to the
controls. Taken together, these results do not support the hy-
pothesis that prior TBI or PTSD is associated with increased
brain amyloid. Furthermore, the worse cognitive functioning
in the PTSD and TBI1 PTSD groups is not associated with
increased brain amyloid. Overall, this interim analysis of an
ongoing study does not support the view that TBI or PTSD is
associated with increased development of AD.
Our first finding of worse cognitive functioning in the
PTSD group confirms previous reports [90–94].
Furthermore, at least one previous study indicates that
PTSD is associated with an increased incidence of dementia
[95]. However, there are no autopsy reports demonstrating
increased AD pathology in Veterans with PTSD. Moreover,
levels of white-matter hyperintensities did not differ among
groups suggesting that the worsening cognitive function in
the PTSD group is not explained by cerebrovascular disease.
Therefore, the cause of cognitive decline or dementia inTable 2
Neuropsychological performance by group
No TBI/PTSD (n 5 63) PTSD (n 5 63)
ADAS-Cogy 10.9 (4.6) 12.8 (3.9)
MMSE 28.7 (1.3) 28.0 (1.7)
CDR Sum of Boxesz 0.19 (0.40) 0.62 (0.82)
RAVLTx 41.3 (9.2) 39.3 (7.4)
Delayed Recalljj 11.1 (3.8) 9.7 (3.8)
Abbreviations: TBI, traumatic brain injury; PTSD, posttraumatic stress disord
Mini–Mental State Examination; CDR, clinical dementia rating; RAVLT, Rey’s a
NOTE. Means and standard deviations are presented.
*P value presented is for the overall group difference in models that adjust for
yTotal score based on 13 items; missing for 1 No TBI/PTSD, 3 PTSD, 1 TBI, a
zMissing for 2 No TBI/PTSD, 3 PTSD, 1 TBI, and 1 TBI 1 PTSD.
xRey Auditory Verbal Learning Test: sum of five trials; missing for 1 No TBI/P
jjLogical Memory II.Veterans with PTSD is not known. The interim results of
our ongoing study do not show increased brain amyloid in
the PTSD group compared to controls. In fact, there is a trend
for reduced brain amyloid in the PTSD group. Although these
results are preliminary, they suggest that the cognitive impair-
ment and dementia associated with PTSD may not be due to
AD pathology.
Hippocampal atrophy has been associated with PTSD in
some studies [66,96–98], but not others [99–102].
Hippocampal atrophy is typically found in AD dementia
but is not specific for this condition [103]. Therefore, our
failure to detect hippocampal atrophy in the PTSD or
TBI 1 PTSD group in this study further suggests that the
cognitive impairments in the PTSD subjects are not due to
AD pathology.
Thus far, our study shows no evidence for increased brain
amyloid load in subjects with prior history of TBI or
TBI 1 PTSD in contrast with previous reports of TBI as a
risk factor for AD. In contrast to most of these reports which
used “self-reported” TBI, we identified subjects from the VATBI (n 5 22) TBI 1 PTSD (n 5 32) P value*
9.4 (3.6) 11.0 (5.2) .10
28.8 (1.1) 28.4 (1.5) .14
0.33 (0.56) 0.47 (0.81) .02
41.3 (9.4) 41.2 (9.1) .46
10.9 (3.3) 11.2 (4.1) .63
er; ADAS-cog, Alzheimer’s Disease Assessment Scale–cognitive; MMSE,
uditory verbal learning test.
age, education, and APOE ε4 allele status.
nd 1 TBI 1 PTSD.
TSD, 3 PTSD, 1 TBI, and 1 TBI 1 PTSD.
Table 3
MRI volumetrics by group
No TBI/PTSD (n 5 52) PTSD (n 5 37) TBI (n 5 16) TBI 1 PTSD (n 5 15) P value*
Hippocampusy 0.51 (0.06) 0.53 (0.06) 0.52 (0.05) 0.51 (0.08) .81
Entorhinal cortexy 0.26 (0.04) 0.28 (0.04) 0.28 (0.02) 0.27 (0.03) .56
Inferior parietaly 1.70 (0.17) 1.74 (0.18) 1.82 (0.15) 1.77 (0.13) .21
Superior parietaly 1.64 (0.16) 1.69 (0.20) 1.71 (0.15) 1.56 (0.13) .046
Inferior temporaly 1.38 (0.15) 1.44 (0.14) 1.41 (0.15) 1.36 (0.12) .35
Superior temporaly 1.42 (0.15) 1.44 (0.15) 1.41 (0.18) 1.47 (0.15) .71
White-matter hyperintensitiesz 6.1 (6.4) 4.4 (3.8) 5.0 (5.5) 4.0 (3.9) .47
Abbreviations: MRI, magnetic resonance imaging; TBI, traumatic brain injury; PTSD, posttraumatic stress disorder.
NOTE. Means and standard deviations are presented.
*P value presented is for the overall group difference in models that adjust for age, education, and APOE ε4 allele status.
yExpressed as percentage of intracranial volume.
zWhite-matter hyperintensities data based on 59 No TBI/PTSD, 53 PTSD, 18 TBI, and 21 TBI 1 PTSD participants.
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that might be related to a traumatic brain injury as well as
by self-report of TBI before, during, and after Vietnam. In
addition, there are no previous studies using Ab florbetapir
PET to determine brain amyloid load, orMRI to detect hippo-
campal atrophy in elders with a past history of TBI. One study
reported greater amyloid deposition in MCI subjects
measured by amyloid PET using Pittsburgh compound B
but head trauma was again self-reported [49]. Although AD
is considered an amyloid-mediated tauopathy, and we have
yet to analyze CSF tau levels or tau-PET imaging results,
our findings thus far lead us to conclude that we have not
found evidence of a connection between past history of TBI
and development of amyloid pathology characteristic of
AD. The present study suggests that TBI may be associated
with cognitive decline unrelated to AD and is, in this regard,
consistent with a report [104] instead showing an association
of TBI with an increased risk of Parkinson’s disease.5. Limitations of the study
Wewish to emphasize the limitations of this interim report.
The first limitation is the small sample size of the TBI group.
Many Veterans who were contacted did not return our calls,
declined to participate, or were unable to participate for a va-
riety of reasons. Compared to subjects who were excluded or
declined, the baseline subjects were slightly younger, and
there were more Caucasians, fewer African Americans, and
more Latinos. Furthermore, for unknown reasons, African
American Veterans had a higher “passive refusal rate” (less
likely to answer the phone, return phone calls, keep anTable 4
Florbetapir cortical SUVR by group
No TBI/PTSD (n 5 54) PTSD (
Cortical SUVR 1.07 (0.14) 1.01 (0
% amyloid positive (SUVR . 1.11) 24.1 5.8
Abbreviations: SUVR, standardized uptake value ratio; TBI, traumatic brain in
NOTE. Means and standard deviations are presented.
*P value presented is for the overall group difference in a model that adjusts foappointment, return consent forms, etc.). These results reflect
a combination of factors including willingness to participate
and comorbidities which led to exclusions. Therefore, the
population which was studied in the clinic differs consider-
ably from the population of subjects who were initially con-
tacted for this project. Despite our efforts to contact and
enroll all Vietnam Veterans receiving compensation from
the VA diagnostic codes that may be related to TBI, we found
that a very high proportion of Veterans with history of TBI
had comorbidities which prevented them from enrolling in
the study. In particular, we found that large numbers of these
Veterans reportedmetal in the body, which preventedMRI ex-
aminations. The prevalence of this exclusion was much
higher than we have experienced in civilian populations stud-
ied in ADNI. However, to increase the number of subjects, the
decision was recently made to waive the MRI for subjects in
the TBI/both cohorts, if the only reason for exclusion was that
MRI was unsafe. In addition, Veterans with both TBI and
PTSD had exclusions for many other reasons and overall
the “screen fail” rate in this study is much higher than we
have experienced with ADNI. These findings serve to empha-
size the well-known observation that clinical research studies
which impose strict inclusion/exclusion criteria to eliminate
comorbidities run the risk of studying a sample that does
not resemble the “general population.” Furthermore, research
studies which include biomarker measurements such as MRI,
PET scans, and lumbar punctures also run the risk of reducing
generalizability.
A second limitation is that our selection of cognitively
normal and MCI participants able to be followed over the
timeframe of the study, rather than of Veterans alreadyn 5 52) TBI (n 5 19) TBI 1 PTSD (n 5 21) P value*
.07) 1.08 (0.20) 1.06 (0.08) .21
21.0 33.3 .04
jury; PTSD, posttraumatic stress disorder.
r age, education, and APOE ε4 allele status.
Fig. 2. Florbetapir cortical SUVR by group and APOE ε4 allele status. The
dotted line represents a previously validated amyloid positivity cutoff of
1.11 [89]. Abbreviations: APOE ε4, apolipoprotein E ε4 allele; PTSD, post-
traumatic stress disorder; SUVR, standardized uptake value ratio; TBI, trau-
matic brain injury.
M.W. Weiner et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 3 (2017) 177-188184exhibiting dementia, may automatically eliminate Veterans
susceptible to the development of AD. The remaining cohort
may represent a portion of the population that does not
develop AD as a result of TBI and/or PTSD.
It is important to emphasize that this is an interim analysis
of an ongoing study. In addition to our continued enrollment
and baseline assessments, we are obtaining 12-month
follow-up data. We are also performing tau-PET imaging
at baseline and 12-month follow-up. Our preliminary results
do not support the hypothesis that either TBI or PTSD in-
creases the risk for AD measured with biomarkers. Subjects
with PTSD do appear to have worse cognition, but this is not
associated with increased amounts of brain amyloid
measured by Ab florbetapir PET scans. In the present study,
we controlled for APOE genotype, the strongest genetic risk
factor for late onset AD. In the future, genome-wide geno-
typing will be available so that other major candidate genes
for AD, PTSD, and TBI can be assessed. When we complete
enrollment, we will test the major hypotheses again, and the
large sample size will provide sufficient statistical power for
additional hypothesis testing and data exploration. Longitu-
dinal data and tau-PET data will also be reported.6. Conclusions
Epidemiological studies have inconsistently linked his-
tory of TBI or PTSD as risk factors for AD although few
have investigated the relationship using imaging or CSF bio-
markers. The study aims to determine the relationship
between a history of TBI and/or PTSD and AD pathology.This preliminary report includes results from baseline clin-
ical examinations, cognitive tests, structural MRI, and Ab
florbetapir PET imaging. Despite finding lower cognitive
functioning in the PTSD and TBI1 PTSD groups, and lower
superior parietal volume in the TBI 1 PTSD group relative
to controls, there was no evidence to suggest that the
observed cognitive decline or atrophy was related to amyloid
deposition. The study was limited by the small sample size
of the TBI group and does not include results from ongoing
tau-PET imaging or CSF biomarker analysis. However, we
conclude that these interim results do not support the hy-
pothesis that either TBI or PTSD increases the risk for AD
as measured by biomarkers.Acknowledgments
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1. Systematic review: The authors reviewed literature
pertaining to the associations between traumatic
brain injury, posttraumatic stress disorder, and cogni-
tive decline, and the incidence and prevalence of
these risk factors in military populations using tradi-
tional sources such as PubMed.
2. Interpretation: Although we observed worse cogni-
tive functioning in veterans with traumatic brain
injury (TBI) and/or posttraumatic stress disorder,
these risk factors did not increase AD risk measured
by amyloid positron emission tomography (PET).
Limitations include difficulty in recruitment due to
exclusions resulting in a small sample size of TBI
subjects and a study population that does not
resemble the “general population.”
3. Future directions: The study will continue to enroll
participants and performed follow-up assessments
of existing participants. Tau-PET imaging at baseline
and 12 months will be performed and major hy-
potheses will be tested again.
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